

Media Release

Zug, 5 December 2017

CSL and HBM Portfolio Company Vitaeris Announce Strategic Partnership with Option to Acquire

CSL Limited (ASX: CSL) and Vitaeris, a privately held company in the portfolio of HBM Healthcare Investments, today announced that they have entered into a strategic partnership to expedite development of clazakizumab (anti-IL6 Mab) as a therapeutic option for solid organ transplant rejection.

Under the terms of the agreement, Vitaeris will retain control of the projects through end of Phase III. Vitaeris will receive an upfront cash payment of USD 15 million from CSL, followed by R&D milestone payments by CSL spanning several years. The agreement also grants CSL an exclusive option to acquire Vitaeris and includes future sales-related payments.

HBM Healthcare Investments is a key founding investor of Vancouver based Vitaeris with an ownership interest of 20 per cent in the company. The current bookvalue of the investment of USD 4 million (invested capital of USD 3 million) remains unchanged.

Clazakizumab is a humanized, monoclonal antibody that binds to and inhibits Interleukin-6 (IL-6). IL-6 is an important driver of the inflammatory response in humans and scientific data shows that IL-6 also plays a key role in transplant rejection.

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

About CSL

CSL (ASX: CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare Investments

prevent influenza. The Company provides life-saving products to more than 60 countries and employs nearly 20,000 people. For more information about CSL Limited, visit www.csl.com.au

About Vitaeris Inc

Vitaeris Inc. is a clinical-stage biopharmaceutical company based in Vancouver, British Columbia, focussed on the development of the anti-interleukin-6 (IL-6) monoclonal antibody clazakizumab for chronic inflammatory diseases. IL-6 is a key cytokine involved in the inflammation of rheumatoid arthritis, and is now being implicated in numerous other diseases characterized by chronic inflammation. Clazakizumab is a best-in-class IL-6 antagonist that has been studied in clinical trials involving over one thousand patients worldwide. For more information, visit www.vitaerisbio.com

Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM Healthcare Investments Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 710 75 77 | Fax: +41 41 710 75 78 | info@hbmhealthcare.com
www.hbmhealthcare.com